Intellia Therapeutics (NTLA) News Today $15.03 -0.11 (-0.73%) (As of 11:11 AM ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Intellia Therapeutics: Positive Outlook and Buy Rating Amid Promising Data for ATTR-CM TreatmentNovember 4 at 10:07 PM | markets.businessinsider.comThis Beaten-Down Stock Could Soar by 354%, According to Wall StreetNovember 4 at 8:00 AM | fool.comIntellia Therapeutics, Inc. (NASDAQ:NTLA) Shares Sold by Capital Advisors Inc. OKCapital Advisors Inc. OK trimmed its stake in shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) by 34.5% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 203,775 shares of the company's stock after selling 107,November 2 at 8:07 AM | marketbeat.comLooking Into Intellia Therapeutics's Recent Short InterestOctober 31, 2024 | benzinga.comIntellia Therapeutics Announces Two Upcoming Investor Events in November 2024October 31, 2024 | finance.yahoo.comIntellia Therapeutics (NTLA): Promising Gene Editing Stock with CRISPR-Cas9 TherapiesOctober 31, 2024 | msn.comIntellia Therapeutics Announces Two Upcoming Investor Events in November 2024October 31, 2024 | globenewswire.comReasons For Intellia Therapeutics Stock Plunge Are Flimsy, But Don't Buck Mr. MarketOctober 30, 2024 | seekingalpha.comIntellia Therapeutics (NASDAQ:NTLA) Reaches New 1-Year Low - Here's What HappenedIntellia Therapeutics (NASDAQ:NTLA) Hits New 12-Month Low - Time to Sell?October 30, 2024 | marketbeat.comIntellia Therapeutics (NASDAQ:NTLA) Shares Down 5.8% - What's Next?Intellia Therapeutics (NASDAQ:NTLA) Trading Down 5.8% - Here's What HappenedOctober 29, 2024 | marketbeat.com12 High-Growth Stocks That Could Deliver Parabolic ReturnsOctober 28, 2024 | fool.comCitigroup Trims Intellia Therapeutics (NASDAQ:NTLA) Target Price to $19.00October 28, 2024 | americanbankingnews.comIntellia Therapeutics Reports Positive Phase 2 Results for NTLA-2002 Treatment for Hereditary AngioedemaOctober 27, 2024 | americanbankingnews.comIntellia Therapeutics (NASDAQ:NTLA) Hits New 52-Week Low Following Analyst DowngradeOctober 26, 2024 | americanbankingnews.comIntellia Therapeutics (NTLA) Gets a Buy from BarclaysOctober 25, 2024 | markets.businessinsider.comIntellia Therapeutics (NASDAQ:NTLA) Price Target Lowered to $19.00 at CitigroupCitigroup reduced their price target on shares of Intellia Therapeutics from $25.00 to $19.00 and set a "neutral" rating on the stock in a research report on Friday.October 25, 2024 | marketbeat.comIntellia Therapeutics (NTLA) Receives a Buy from OppenheimerOctober 25, 2024 | markets.businessinsider.comIntellia Therapeutics price target lowered to $65 from $80 at BofAOctober 25, 2024 | msn.comIntellia reports positive data from Phase II study of NTLA-2002 for HAEOctober 25, 2024 | finance.yahoo.comMonopar Therapeutics, Intellia Therapeutics, Capri Holdings, Western Digital, And Tesla: Why These 5 Stocks Are On Investors' Radars TodayOctober 25, 2024 | benzinga.comIntellia's Ntla-2002 Shows Promising Results, but Stock Drops Following Phase 2 Data ReleaseOctober 25, 2024 | finance.yahoo.comCathie Wood’s ARK Investment buys 216.2K shares of Intellia Therapeutics todayOctober 25, 2024 | markets.businessinsider.comIntellia Therapeutics price target lowered to $88 from $94 at ChardanOctober 25, 2024 | markets.businessinsider.comIntellia Therapeutics stock plunges after phase 2 results from NTLA-2002 studyOctober 25, 2024 | msn.comWhy Intellia Therapeutics Stock Plummeted by 20% TodayOctober 24, 2024 | fool.comIntellia Therapeutics (NASDAQ:NTLA) Given New $88.00 Price Target at Chardan CapitalChardan Capital cut their target price on shares of Intellia Therapeutics from $94.00 to $88.00 and set a "buy" rating on the stock in a research note on Thursday.October 24, 2024 | marketbeat.comIntellia Therapeutics, Inc. (NTLA) Call to Discuss NTLA-2002 Phase 2 Study Results TranscriptOctober 24, 2024 | seekingalpha.comIntellia Therapeutics (NASDAQ:NTLA) Hits New 12-Month Low - Here's WhyIntellia Therapeutics (NASDAQ:NTLA) Hits New 1-Year Low - What's Next?October 24, 2024 | marketbeat.comIntellia Presents Positive Results from the Phase 2 Study of NTLA-2002, an Investigational In Vivo CRISPR Gene Editing Treatment for Hereditary Angioedema (HAE)October 24, 2024 | globenewswire.comIntellia Therapeutics (NASDAQ:NTLA) Trading Down 7.3% - Here's WhyIntellia Therapeutics (NASDAQ:NTLA) Trading Down 7.3% - Here's WhyOctober 23, 2024 | marketbeat.comIntellia Therapeutics, Inc. (NASDAQ:NTLA) Receives Average Rating of "Moderate Buy" from AnalystsIntellia Therapeutics, Inc. (NASDAQ:NTLA - Get Free Report) has earned a consensus recommendation of "Moderate Buy" from the fifteen research firms that are presently covering the firm, Marketbeat reports. Four analysts have rated the stock with a hold recommendation, ten have assigned a buy recomOctober 22, 2024 | marketbeat.comIntellia Therapeutics’ NTLA-2002 Shows Promise with Potential Stock SurgeOctober 21, 2024 | markets.businessinsider.comThis Beaten-Down Growth Stock Could Skyrocket 234%, According to Wall StreetOctober 17, 2024 | fool.comIntellia Therapeutics (NTLA) to Release Quarterly Earnings on ThursdayIntellia Therapeutics (NASDAQ:NTLA) will be releasing earnings before the market opens on Thursday, October 24, Zacks reports. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=616557)October 17, 2024 | marketbeat.comIntellia Therapeutics, Inc. (NTLA) the Most Promising Biotech Stock According to Hedge Funds?October 16, 2024 | msn.comIntellia Therapeutics: Promising Outlook with NTLA-2002’s Impressive Phase II Results and Competitive EdgeOctober 16, 2024 | markets.businessinsider.comIs Intellia Therapeutics, Inc. (NTLA) the Most Promising Biotech Stock According to Hedge Funds?October 16, 2024 | finance.yahoo.comIntellia Therapeutics, Inc. (NASDAQ:NTLA) Shares Sold by Squarepoint Ops LLCSquarepoint Ops LLC reduced its holdings in Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) by 94.6% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 13,280 shares of the company's stock after selOctober 12, 2024 | marketbeat.comIntellia Therapeutics (NASDAQ:NTLA) Hits New 1-Year Low - What's Next?Intellia Therapeutics (NASDAQ:NTLA) Reaches New 1-Year Low - Here's What HappenedOctober 10, 2024 | marketbeat.comIntellia Therapeutics Announces New Date for Upcoming Investor WebcastOctober 10, 2024 | globenewswire.comIntellia Therapeutics Inc (NTLA) Q2 2024 Earnings Call Highlights: Strategic Advances and ...October 9, 2024 | finance.yahoo.comTruist Financial Initiates a Buy Rating on Intellia Therapeutics (NTLA)October 9, 2024 | markets.businessinsider.com2 Cathie Wood Stocks That Could Soar 32% and 282%, According to Wall StreetOctober 9, 2024 | fool.com30,333 Shares in Intellia Therapeutics, Inc. (NASDAQ:NTLA) Purchased by Thrivent Financial for LutheransThrivent Financial for Lutherans bought a new position in Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 30,333 shares of the company's stock, valued at aOctober 8, 2024 | marketbeat.comIntellia Therapeutics’ Gene Editing Potential Bolsters Buy Rating Amidst Promising HAELO Study ProgressOctober 8, 2024 | markets.businessinsider.comIntellia Therapeutics: A Strong Buy on Promising Trials and Financial StabilityOctober 7, 2024 | markets.businessinsider.comIntellia Therapeutics Announces Initiation of HAELO Phase 3 Study of NTLA-2002, an Investigational In Vivo CRISPR Gene Editing Treatment for Hereditary Angioedema (HAE)October 7, 2024 | globenewswire.comHealthcare of Ontario Pension Plan Trust Fund Sells 99,532 Shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA)Healthcare of Ontario Pension Plan Trust Fund decreased its holdings in shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) by 41.8% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 138,468 shares of the cOctober 7, 2024 | marketbeat.comMichael P. Dube Sells 2,012 Shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA) StockOctober 5, 2024 | insidertrades.comBuy Rating on Intellia Therapeutics Backed by Promising Phase 1 Study and Upcoming Data PresentationOctober 4, 2024 | markets.businessinsider.com Get Intellia Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for NTLA and its competitors with MarketBeat's FREE daily newsletter. Email Address Market "Famine" Coming (Ad)Market Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicted the 2020 crash a month before it happened... For a limited time, he's revealing his latest forecast here. NTLA Media Mentions By Week NTLA Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. NTLA News Sentiment▼0.360.44▲Average Medical News Sentiment NTLA News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. NTLA Articles This Week▼105▲NTLA Articles Average Week Get Intellia Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for NTLA and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Celldex Therapeutics News Sangamo Therapeutics News Editas Medicine News Cellectis News CRISPR Therapeutics News Nuvalent News Blueprint Medicines News Krystal Biotech News Avidity Biosciences News Arcellx News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:NTLA) was last updated on 11/5/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredBiden to Launch “FedNOW” [Move Your Money Now]Earlier this year President Biden signed the death warrant for America… Executive Order 14067 will essentia...Priority Gold | SponsoredBlackrock’s Sending THIS Crypto Higher on PurposeIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredMissed Out On Nvidia?Artificial Intelligence is a tool with the potential to create massive distributions of wealth… In fact, it...Unstoppable Prosperity | SponsoredThis company will win the AI race Rome wasn’t built in a day… But there is another lesser-known type of keystone, one that plays an equally c...Porter & Company | Sponsored626 winning trades out of 647…Imagine turning nearly every Friday into a payday. That's exactly what one reclusive multi-millionaire trad...Investing Daily | Sponsored625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Intellia Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Intellia Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
